Navigation Links
Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief

Endomorphins are highly powerful a tool for pain management, just as morphine, a problematic narcotic derived from the opium poppy. It has previously been found that endomorphins are able to sidestep concerns// of side effects by virtue of their hard-wired relationship to the body's own pain control receptors. Such receptors, known as u-opioids, appear to be highly sensitized to endomorphins, selectively drawing the natural analgesic to their target spots throughout the peripheral tissue of joints.

Recently a study, published in the October issue of Arthritis and Rheumatism, was conducted to determine whether peripheral administration of the endogenous - opioid peptide endomorphin 1 could reduce knee joint pain, using animal models of acute and chronic arthritis.

Researchers from the University of Calgary, Alberta, Canada looked at the effect of endomorphin 1 on both acute and chronic arthritis in male lab rats. After inducing inflammation in their right knee joints, the researchers treated the rats with endomorphin 1 at various points following the onset of knee arthritis -- either 48 hours post-inflammation during the acute stage of joint pain, or at the one-week or three-week point during the chronic stage.

At all stages of treatment, the electrical activity, or firings, of knee nerve-endings in response to an exaggerated rotation of the joint were measured. Nerve-ending readings were also taken among rats that did not have arthritic knees but were nonetheless also treated with endomorphin.

The researchers found that endomorphin treatment caused nerve activity -- and presumably any related pain -- to drop off by approximately 75% in both normal rats and those with acute arthritis of the knee. However, when injected one or three weeks after the onset of arthritis, endomorphin had no effect on nerve activity. Subsequent autopsies further revealed that beginning one week after induced knee joint inflamm ation, the numbers and activity levels of some local u-opioid receptors had dropped below normal. At three weeks, all receptor activity levels dropped off significantly.

Immunohistochemical and real-time PCR analysis of the L3-L5 dorsal root ganglia ipsilateral to the chronic arthritis lesion revealed a reduction in -opioid receptor protein and gene expression compared with that in normal control animals.

The study concludes on the note that endomorphin, the morphine-like pain control agent, does not have any observable effect on reducing the sensitivity of arthritic joint nerves in the long run. The analgesic effect of endomorphin 1 is lost during chronic inflammation due to down-regulation of -opioid receptor expression in afferent nerve cell bodies. The therapy did, however, provoke a dramatic reduction in short-term joint hypersensitivity. These findings begin to explain the ambiguous efficacy of peripherally administered -opioid drugs in controlling chronic inflammatory joint pain.
'"/>




Related medicine news :

1. Efficacy Of Meningitis C Vaccine
2. The Efficacy Of Allergy Shots Questioned
3. The Efficacy Of Newer Stents Questioned
4. The Efficacy Of Hormone Replacement Therapy Studied
5. Efficacy of fish oil supplements in pregnancy.
6. Efficacy of Omega 3 Fatty Acids Needs Wider Perspective
7. Thailand To Test Efficacy Of Stem Cell Technology
8. Efficacy Of Sports-Formulated Jelly Beans In Warding Off Fatigue To Be Studied
9. Indian And Chinese Doctors Join Together To Prove The Efficacy Of Herbal Drugs
10. New Study Shows Efficacy of AROMASIN on Early Breast Cancer
11. KADIAN Efficacy Not Affected by Alcohol Consumption
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/22/2017)... ... ... Despite its pervasiveness, many physicians are unfamiliar with how best to treat ... practice. Now, however, a timely review has been published in the Journal of ... NeuP and educating preclinical scientists on its diagnosis and choice of treatment. , The ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., ... a new eBook titled “ 5 Questions to Ask Before Entering the Maze ... the Genetic Test Evaluation (GTE) team, the book explores the various types of ...
(Date:6/20/2017)... ... 20, 2017 , ... AMC Health , the leading provider of proven ... trials market. Similar to its approach in demonstrating positive outcomes in the healthcare market, ... proving the value of eVisits to support virtual studies. , In a ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts ... NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their practice ... can cause for some patients, which is why they offer the latest in modern ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
Breaking Medicine Technology: